Guru Sonpavde

Also affiliated with AdventHealth Orlando, AdventHealth East Orlando, Florida Hospital Cancer Institute, Dana-Farber Cancer Institute, UnitedHealth Group (United States)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile

0.427Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008724

Top 44%

0.427DataRank

Top 44%8 citations

Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame +28 more

Papers

Driven by 38 papers — median percentile 28. Top paper: “Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma”.

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine(2024)10.1056/nejmoa2401726

N/A

3.9DataRank · unranked

151 citations

Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Atul Parikh +35 more

Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies

Cancer(2020)10.1002/cncr.33328

N/A

3.1DataRank · unranked

113 citations

Matthew T. Campbell, Wanling Xie, Subrina Farah, Mehmet Asım Bilen, Andrew Schmidt +11 more

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer

JAMA Network Open(2021)10.1001/jamanetworkopen.2020.34633

N/A

2.0DataRank · unranked

43 citations

Lance K. Heilbrun, Paul Monk, Sheela Tejwani, Guru Sonpavde, Clara Hwang +10 more

Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008724

Top 44%

0.427DataRank

Top 44%8 citations

Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame +28 more

A pilot study of [18F]F-fluciclovine positron emission tomography/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy

European Journal of Nuclear Medicine and Molecular Imaging(2025)10.1007/s00259-025-07287-y

N/A

0.173DataRank · unranked

2 citations

Mofei Liu, Matthew Robertson, Arda Könik, Su Cheng, Martin Bakht +10 more

Real-world prognostic model for overall survival (OS) in patients (pts) with advanced urothelial cancer (aUC) treated with immune checkpoint inhibitors (ICI).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.447

Top 100%

0DataRank

Top 100%0 citations

Leonidas Nikolaos Diamantopoulos, Natalie Miller, Mehmet Asım Bilen, Víctor Sacristán Santos, Rafael Morales‐Barrera +15 more

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Cancer(2021)10.1002/cncr.34057

N/A

0DataRank · unranked

86 citations

Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Amanda Nizam +31 more

Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.04.008

N/A

0DataRank · unranked

38 citations

Archana M. Agarwal, Moshe Chaim Ornstein, Jorge García, Ruby Gupta, Petros Grivas +11 more

RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics

Journal of Clinical Investigation(2021)10.1172/jci147849

N/A

0DataRank · unranked

34 citations

Amruta S. Samant, Amin H. Nassar, Jonathan So, Elizabeth P. Garcia, Catherine R. Curran +13 more

Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes

British Journal of Urology(2021)10.1111/bju.15324

N/A

0DataRank · unranked

28 citations

Ali Raza Khaki, Leonidas Nikolaos Diamantopoulos, Lucía Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky +41 more

Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform

The Oncologist(2021)10.1002/onco.13869

N/A

0DataRank · unranked

16 citations

Andrew W. Hahn, Roberto Nussenzveig, Sergiusz Wesołowski, Nicolas Sayegh, Benjamin L. Maughan +11 more

Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors

European Journal of Cancer(2021)10.1016/j.ejca.2021.07.031

N/A

0DataRank · unranked

16 citations

Sarah E. Street, Ian A. Strohbehn, Meghan Lee, Sophia H. Zhao, Nifasha Rusibamayila +16 more

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma

BJUI Compass(2021)10.1002/bco2.125

N/A

0DataRank · unranked

15 citations

Talal El Zarif, Rohit Jain, William Paul Skelton, Dory Freeman, Catherine Curran +8 more

Association of prior local therapy and outcomes with programmed‐death ligand‐1 inhibitors in advanced urothelial cancer

British Journal of Urology(2021)10.1111/bju.15603

N/A

0DataRank · unranked

5 citations

Rafee Talukder, Leonidas Nikolaos Diamantopoulos, Lucía Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky +42 more

Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

Cancer Cell(2022)10.1016/j.ccell.2022.08.022

N/A

0DataRank · unranked

118 citations

Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W. Akl +27 more

TUBB4A interacts with MYH9 to protect the nucleus during cell migration and promotes prostate cancer via GSK3β/β-catenin signalling

Nature Communications(2022)10.1038/s41467-022-30409-1

N/A

0DataRank · unranked

67 citations

Shuaibin Wang, Zhiying Zhao, Chao Zhang, Zhicao Liu, Ping Ye +12 more

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors

JCI Insight(2022)10.1172/jci.insight.155899

N/A

0DataRank · unranked

65 citations

Darshan S. Chandrashekar, Chakravarthi Balabhadrapatruni, Saroj Nepal, Sai Akshaya Hodigere Balasubramanya, Abigail Shelton +15 more

Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.06.001

N/A

0DataRank · unranked

28 citations

Rafee Talukder, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta +47 more

Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials

The American Journal of Medicine(2022)10.1016/j.amjmed.2022.03.042

N/A

0DataRank · unranked

27 citations

Mahnoor Islam, Ahsan Masood Khan, Syed Arsalan Ahmed Naqvi, Rabbia Siddiqi, Kaneez Zahra Rubab Khakwani +11 more

Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.04.012

N/A

0DataRank · unranked

23 citations

Elio Adib, Nicole Weise, Catherine Curran, Tyler F. Stewart, Dory Freeman +9 more

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.08.006

N/A

0DataRank · unranked

9 citations

Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta +49 more

Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps595

N/A

0DataRank · unranked

12 citations

Youngchul Kim, Jennifer Rembisz, Richard Piekarz, Timothy W. Synold, Jingsong Zhang +2 more

Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps591

N/A

0DataRank · unranked

1 citations

Melissa Plets, Michael A. Liss, Joshua J. Meeks, Daniel P. Petrylak, Suzanne Cole +9 more

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad155

N/A

0DataRank · unranked

56 citations

Amin H. Nassar, Gregory R. Pond, Tony Zhuang, Viraj A. Master, Bassel Nazha +50 more

Total Margin Control Is Superior to Traditional Margin Assessment for Treatment of Low-Stage Penile Squamous Cell Carcinoma

The Journal of Urology(2023)10.1097/ju.0000000000003736

N/A

0DataRank · unranked

3 citations

Jacob L. Thomas, Fadi Murad, Guohai Zhou, Guru Sonpavde, Matthew Mossanen +7 more

A CD24-p53 axis contributes to African American prostate cancer disparities

UNC Libraries(2023)10.17615/wkpv-na27

N/A

0DataRank · unranked

0 citations

Elizabeth T. H. Fontham, James L. Mohler, Ran Liu, Kun Zhang, Wei Liu +8 more

Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis

BMJ Oncology(2024)10.1136/bmjonc-2024-000335

N/A

0DataRank · unranked

20 citations

Giovanni Maria Iannantuono, Saad Atiq, Dilara Akbulut, Ninet Sinaii, Nicholas I. Simon +11 more

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.03.011

N/A

0DataRank · unranked

15 citations

Talal El Zarif, Ramya Ramaswami, Amin H. Nassar, Elio Adib, Noha Abdel‐Wahab +25 more

New Therapeutic Horizons for Advanced or Metastatic Penile Cancer

Urologic Clinics of North America(2024)10.1016/j.ucl.2024.03.005

N/A

0DataRank · unranked

7 citations

Saad Atiq, Guru Sonpavde, Andrea B. Apolo, N. Simon

Factors predictive of recurrence, metastasis and death in node‐negative penile squamous cell carcinoma: A retrospective multicentre cohort study

Journal of the European Academy of Dermatology and Venereology(2024)10.1111/jdv.20093

N/A

0DataRank · unranked

3 citations

Jacob L. Thomas, Fadi Murad, Guohai Zhou, Guru Sonpavde, Matthew Mossanen +6 more

Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.08.003

N/A

0DataRank · unranked

4 citations

Carlos Riveros, Guru Sonpavde, Andrea B. Apolo, Aly‐Khan A. Lalani, Christopher J.D. Wallis +2 more

Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and Leukemia Volume 24, Issue 8, August 2024, Pages 523-530]

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.10.011

N/A

0DataRank · unranked

0 citations

Talal El Zarif, Ramya Ramaswami, Amin H. Nassar, Elio Adib, Noha Abdel‐Wahab +25 more

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

Journal of Clinical Oncology(2025)10.1200/jco-25-01608

N/A

0DataRank · unranked

16 citations

Matthew D. Galsky, Nazlı Dizman, David H. Aggen, Neeraj Agarwal, Hikmat Al‐Ahmadie +39 more

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States

UNC Libraries(2025)10.17615/bc35-y591

N/A

0DataRank · unranked

0 citations

Praful Ravi, Robert A. Baiocchi, Noha Abdel‐Wahab, Swetha Kambhampati, Talal El Zarif +25 more

Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors

Cancer Immunology Research(2020)10.1158/2326-6066.cir-19-0866

N/A

0DataRank · unranked

79 citations

Amin H. Nassar, Wanling Xie, Ziad Bakouny, Jacob E. Berchuck, David A. Braun +27 more

PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression

Matrix Biology(2020)10.1016/j.matbio.2020.01.001

N/A

0DataRank · unranked

23 citations

Anirban Kundu, Garrett J. Brinkley, Darshan S. Chandrashekar, Richard Kirkman, Balabhadrapatruni V. S. K. Chakravarthi +9 more

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

Cancer(2020)10.1002/cncr.33067

N/A

0DataRank · unranked

35 citations

Michael R. Harrison, Peter H. O’Donnell, Ajjai Alva, Noah M. Hahn, Leonard J. Appleman +17 more

Histologic subtype and response to immune checkpoint inhibitor (ICI) therapy in advanced urothelial cancer (aUC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.495

N/A

0DataRank · unranked

0 citations

Ali Raza Khaki, Leonidas Nikolaos Diamantopoulos, Mehmet Asım Bilen, Víctor Sacristán Santos, Rafael Morales‐Barrera +15 more

Guru Sonpavde

Indexed papers

Top data-sharing exemplar

Papers